Date: 2015-08-20
Type of information: Development agreement
Compound: AXL1717 (picropodophyllin)
Company: Axelar (Sweden) Cadila Pharmaceuticals (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: AXL1717 - picropodophyllin is a targeted oral small-molecule insulin-like growth factor 1 (IGF-1) receptor pathway inhibitor with no observable effect on the closely related insulin receptor. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as a promising target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market. Axelar is currently running a randomized Phase II clinical trial with AXL1717 in non-small cell lung cancer patients. A first-in-man Phase I/II clinical trial with AXL1717 including 49 patients has been completed demonstrating a good tolerability profile of the compound, in addition to its superior preclinical efficacy against numerous tumors.
Disease: non-small cell lung cancer (NSCLC)
Details: * On August 20, 2015, Axelar and Cadila Pharmaceuticals announced that they have entered into a co-development agreement for further formulation development and clinical development of AXL1717 in
patients with non-small cell lung cancer (NSCLC).
Under the terms of the agreement, Cadila Pharmaceuticals will perform formulation development on AXL1717, as well conduct a multicentre randomized Phase II study in patients with non-small cell lung cancer in India. Cadila Pharma will co-invest a proportion of the projected costs for the formulation development and clinical trials and will in return, receive defined geographic market rights for AXL1717 and revenue sharing in future licence
deals for AXL1717.
Financial terms:
Latest news:
